Scheduled seven-day lenvatinib administration followed by transarterial chemoembolization achieved a median progression-free survival of 8.0 months and a 12-month local recurrence-free survival rate of 75.9% in patients with unresectable hepatocellular carcinoma.
Observational (n=25)
No
Does seven-day administration of lenvatinib followed by conventional transarterial chemoembolization improve local tumor control and imaging findings in patients with unresectable hepatocellular carcinoma?
Purpose: To retrospectively evaluate local tumor control and imaging findings after seven-day administration of lenvatinib followed by conventional transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Kageyama et al. (Tue,) conducted a observational in Unresectable hepatocellular carcinoma (n=25). Lenvatinib followed by conventional transarterial chemoembolization (TACE) was evaluated on Median progression-free survival (months) (95% CI 6.0-8.5). Scheduled seven-day lenvatinib administration followed by transarterial chemoembolization achieved a median progression-free survival of 8.0 months and a 12-month local recurrence-free survival rate of 75.9% in patients with unresectable hepatocellular carcinoma.